NANOV.OL

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Earnings surprises

Beat consensus in 4 of the last 7 reported quarters

Reported	Est. EPS	Actual	Surprise
2021-11-18	$-1.09	$-1.10	-0.9%
2021-08-27	$-1.19	$-1.04	+12.6%
2021-05-26	$-1.19	$-1.19	+0.0%
2021-02-18	$-0.89	$-1.37	-53.9%
2020-11-19	$-1.47	$-1.31	+10.9%
2020-08-27	$-1.76	$-1.84	-4.5%
2020-05-26	$-1.86	$-1.39	+25.3%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
NANOV.OLNordic Nanovector ASA	$1.93	-3.30%	$451M	—
BGBIO.OLBerGenBio ASA	$1.17	+0.00%	$46M	—
PCIB.OLPCI Biotech Holding ASA	$0.07	+0.00%	$3M	—
RECSI.OLREC Silicon ASA	$0.23	+0.00%	$94M	—
TRVX.OLTargovax ASA	$0.59	+0.00%

Nordic Nanovector ASA

Nordic Nanovector ASA, an Oslo, Norway-based biopharmaceutical firm, is dedicated to conceiving and commercializing treatments for hematological (blood) cancers. Its most advanced therapeutic, Betalutin—a CD37-targeting antibody-radionuclide conjugate—is currently undergoing Phase 2b clinical trials for individuals afflicted with non-Hodgkin lymphoma. The company's preclinical portfolio also features Alpha37, an anti-CD37 alpha-particle emitting radioimmunoconjugate being investigated for chronic lymphatic leukemia. Nordic Nanovector has forged collaboration agreements with several partners, such as the Paul Scherrer Institute, ArevaMed, LegoChem Bio, and Heidelberg Pharma. Additionally, it maintains a research partnership with the University of Pennsylvania to develop a CD37-targeting CAR-T cell strategy aimed at B-cell malignancies. Incorporated in 2009, the enterprise was formerly known as Nordic Nanovector AS before adopting its current name in 2014.

www.nordicnanovector.com

Employees: 18
IPO / List date: Mar 23, 2015
HQ: NO

Held by traders on TradeandTell

No one on the platform currently holds NANOV.OL.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in NANOV.OL as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded NANOV.OL yet.